Randomized controlled study of oxaliplatin combined with tegafur and calcium folinate in treatment of advanced gastric cancer

Abstract

Objective To compare the efficacy and safety of oxaliplatin combined with tegafur and calcium folinate with FOLFOX4 regimens on patients with advanced gastric cancer. Methods 120 patients with advanced gastric cancer were randomly divided into two groups. concluding 60 cases in observation group (modified group) treated with oxaliplatin combined with tegafur and leucovorin and 60 cases in control group (FOLFOX4 group) treated with oxaliplatin combined with calcium folinate and fluorouracil. Clinical efficacy was evaluated after 2 (3-6) cycles. Results The clinical efficacy rates of observation group and control group were 63.3 ％ (38/60) and 41.7 ％ (25/60), respectively (x2 =5.647, P =0.028). The median progression-free survival and median overall survival of patients in observation group were 7.7 months and 11.6 months,respectively, and those in control group were 7.3 months and 10.1 months, respectively. The median progression-free survival (P =0.032) and median overall survival (P =0.005) were statistically significant differences. The increased ratio of Karnofsky score of patients in observation group was higher than that in control group (P =0.015). The incidence of myelosuppression in observation group was lower than that in control group (P =0.044). There was no significant difference between the two groups on other adverse reaction rates. Conclusion The efficacy and safety of oxaliplatin plus tegafur and leucovorin in the treatment of advanced gastric cancer is superior to FOLFOX4 regimen, and worthy of clinical application. Key words: Stomach neoplasms; Treatment outcome; Oxaliplatin; Tegafur, Calcium folinate